Zevra Therapeutics, Inc.

NasdaqGS:ZVRA Stock Report

Market Cap: US$462.2m

Zevra Therapeutics Past Earnings Performance

Past criteria checks 0/6

Zevra Therapeutics's earnings have been declining at an average annual rate of -18.8%, while the Pharmaceuticals industry saw earnings growing at 2.1% annually. Revenues have been growing at an average rate of 6.9% per year.

Key information

-18.8%

Earnings growth rate

53.2%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate6.9%
Return on equity-128.5%
Net Margin-366.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results

Nov 15
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%

Aug 30
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors

Jul 12
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors

Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically

Apr 07
Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Apr 04
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

Apr 02
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Dec 28
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts

Sep 05
Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts

This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year

Aug 20
This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable

Apr 17
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable

US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results

Mar 10
US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results

Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?

Mar 08
Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?

Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates

Nov 16
Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates

Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?

Nov 11
Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?

KemPharm posts Phase 1 data to support further studies for sleep disorder therapy

Sep 28

KemPharm wins Buy rating at Canaccord on CNS focus

Sep 15

KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety

Jun 28

KemPharm exercises existing warrants and issues new ones in private placement

Jun 18

Revenue & Expenses Breakdown

How Zevra Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ZVRA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2424-905444
30 Jun 2424-674446
31 Mar 2428-493843
31 Dec 2327-463539
30 Sep 2317-242534
30 Jun 2317-172327
31 Mar 239-382025
31 Dec 2210-271619
30 Sep 2211-351316
30 Jun 2210-301112
31 Mar 2220-171010
31 Dec 2129-63910
30 Sep 2128-65910
30 Jun 2128-6699
31 Mar 2123-5588
31 Dec 2013-1388
30 Sep 2012-1478
30 Jun 2022-81010
31 Mar 2015-181112
31 Dec 1913-251119
30 Sep 1911-241323
30 Jun 190-421232
31 Mar 190-431338
31 Dec 180-561341
30 Sep 180-621341
30 Jun 180-571333
31 Mar 180-531328
31 Dec 170-431320
30 Sep 170-431323
30 Jun 170-451321
31 Mar 170-301421
31 Dec 160-171420
30 Sep 160-161417
30 Jun 160-131317
31 Mar 160-521215
31 Dec 150-55914
30 Sep 150-57815
30 Jun 150-55714
31 Mar 150-29513
31 Dec 140-24512
30 Sep 140-1437

Quality Earnings: ZVRA is currently unprofitable.

Growing Profit Margin: ZVRA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ZVRA is unprofitable, and losses have increased over the past 5 years at a rate of 18.8% per year.

Accelerating Growth: Unable to compare ZVRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZVRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: ZVRA has a negative Return on Equity (-128.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies